Learning Ability Support Humanin Peptide Lyophilized 99% Purity 5-20mg Vials CAS 330936-69-1

1.  Description

Chemical properties: Humanin belongs to linear peptides, with an amino acid sequence of Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Val-Lys-Arg-Arg-Ala-Ser-Leu-Pro-Tyr-Ser-Leu-Leu-Lys， The molecule contains cysteine residues but no disulfide bonds, and its core targets include amyloid (A β) aggregation sites, apoptosis related proteins (such as Bax), and mitochondrial membrane receptors. The chemical properties are relatively stable, and it is not easily hydrolyzed in neutral to weakly alkaline (pH 6.5-8.0) environments. Its ability to resist peptidase degradation is superior to short chain peptides, and it has good compatibility with mitochondrial protective components such as phosphatidylcholine and coenzyme Q10.
     Physical properties: Humanin is a white to off white crystalline powder at room temperature, odorless and tasteless, with moderate water solubility (solubility ≥ 25 mg/mL), easily soluble in dimethyl sulfoxide (DMSO), ethanol, and insoluble in non-polar solvents such as petroleum ether. The molecular weight is 26 kDa (note: the actual molecular formula is C ₁₂₄ H ₂₀₈ N ∝₆ O ∝₁ S, with an accurate molecular weight of 2759.5 Da), and it needs to be stored under dry, sealed, and dark conditions at -20 ℃ to avoid repeated freezing and thawing; Research grade product purity ≥ 98% (HPLC detection), single impurity ≤ 1.0%, no endotoxins and heavy metal residues.
     Source and preparation: Humanin naturally exists in human mitochondria and is the first mitochondrial encoded peptide discovered. In industry, precise preparation is achieved through solid-phase peptide synthesis, using high-purity L-type amino acids as raw materials, followed by condensation, deprotection, peptide chain assembly, and finally purified by high-performance liquid chromatography (HPLC) to obtain high-purity products; The synthesis process strictly controls the reaction conditions to ensure the integrity of the peptide chain structure and biological activity, and verifies the product quality through mass spectrometry (MS) and amino acid sequence analysis.

2.  Application

      Biomedical research field (core application): Humanin, as a core tool reagent for studying neuroprotective mechanisms, is used to explore the mechanisms of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Analyze the regulatory effects of neuronal cells, mitochondrial damage model cells (such as A β - induced neuronal apoptosis model), and transgenic disease model mice on neuronal cell survival, mitochondrial function, and amyloid protein aggregation, providing experimental evidence for the development of neuroprotective drugs.
    Preclinical pharmaceutical development field: Humanin is used as a candidate drug for preclinical research and development of neurodegenerative and cardiovascular diseases. Exploring the potential of inhibiting A β toxicity and improving cognitive function in Alzheimer's disease; To verify the mitochondrial protection and anti cardiomyocyte apoptosis effects against myocardial ischemia-reperfusion injury; At present, it has entered the animal level activity verification stage, and some derivatives (such as S14G Humanin) have shown stronger biological activity and stability.
     High end anti-aging and functional health care field: Humanin is based on mitochondrial protection and anti apoptotic properties, and has the potential to be applied in anti-aging dietary supplements and neurological health care products. Targeting middle-aged and elderly populations 

3. Main Efficacy

Neuroprotective and anti apoptotic core effects: The core mechanism of Humanin is competitive binding to the apoptotic protein Bax, which prevents Bax from inserting into the mitochondrial membrane and triggering the cell apoptosis pathway; Simultaneously inhibiting the aggregation and toxic effects of amyloid beta protein (A β), reducing the damage of A β to neurons, and improving the survival rate of nerve cells. In the Alzheimer's disease model, Humanin can significantly improve cognitive function in mice, reduce neuronal loss in the hippocampus, and delay disease progression.
     Mitochondrial repair and energy metabolism optimization effects: Humanin targets damaged mitochondria, stabilizes mitochondrial membrane potential, repairs mitochondrial electron transport chain function, and enhances ATP generation efficiency; Eliminate reactive oxygen species (ROS) produced by mitochondria, reduce oxidative stress damage to mitochondrial DNA (mtDNA), reverse mitochondrial fragmentation, and restore normal mitochondrial morphology and function. In the myocardial ischemia model, it can reduce the apoptosis rate of myocardial cells and improve cardiac contractile function.
     Anti inflammatory and multi tissue protective effects: Humanin inhibits the release of pro-inflammatory factors (TNF - α, IL-6), reducing neuroinflammation and systemic inflammatory responses; It has a protective effect on ischemic damage to organs such as the liver and kidneys, reducing tissue necrosis and accelerating injury repair through anti apoptotic and antioxidant mechanisms; At the same time, it can regulate insulin sensitivity and improve diabetes related neuropathy and vascular damage.
      Safety advantages: As an endogenous peptide in the human body, Humanin has extremely high biocompatibility, no cytotoxicity (MTT assay shows that the survival rate of nerve cells is>98% when the concentration is ≤ 5 μ mol/L), no mutagenicity, and no reproductive toxicity; Long term low-dose use has no significant adverse reactions and is not prone to drug resistance, making it suitable for long-term treatment and health maintenance scenarios.